Research
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – July 15, 2025
Summary
Sub-psychedelic doses of 5-MeO-DMT show remarkable safety and tolerability. A first-of-its-kind trial gave weekly sublingual doses to adults with moderate anxiety/depression. Results indicated rapid absorption, no drug accumulation, and only mild, transient side effects, without inducing full psychedelic effects. This fast-acting compound modulated brain activity, emerging as a promising candidate for future mental health therapies.
Abstract
This Phase I clinical trial is the first to rigorously evaluate the safety, tolerability, and pharmacokinetics of a novel sublingual formulation of...
Acute and long-term effects of repeated ketamine infusions in treatment-resistant depression and associated metabolite changes.
Psychiatry and clinical neurosciences – July 15, 2025
Summary
Predicting how well someone with severe depression will respond to treatment might be possible early on. Researchers explored if repeated ketamine infusions could help those with treatment-resistant depression. They found these infusions rapidly improved symptoms, with some patients achieving sustained relief. Crucially, changes in a specific metabolite, 3-hydroxybutyrate, measured via metabolomics after the first ketamine dose, predicted long-term improvements in depression. This suggests a powerful way to personalize future depression care.
Abstract
This study aims to investigate the acute and sustained antidepressant effects of repeated ketamine infusions in patients with treatment-resistant d...
Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review.
Current microbiology – July 15, 2025
Summary
Beyond traditional use, certain mushrooms contain compounds showing remarkable promise for mental health. A review of scientific literature explores the chemical makeup and genetic diversity of Psilocybe species. It reveals significant therapeutic potential for treating conditions like depression, anxiety, and addiction, suggesting a promising future for these natural agents.
Abstract
Psilocybe species, commonly known as "magic mushrooms", are a group of hallucinogenic fungi known for their psychoactive compounds such as psilocyb...
Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers
Australian & New Zealand Journal of Psychiatry – July 15, 2025
Summary
Australian mental healthcare providers generally support Psilocybin and other Psychedelics for mental health, yet significant concerns persist. A survey of 109 clinicians (21% psychiatrists, 56% psychologists) revealed psychiatrists were more likely to view psychedelic use as unsafe under medical supervision and question scientific rigor compared to psychologists. While attitudes toward this emerging field of medicine are positive, particularly among those with personal experience of drug studies, gaps in evidence-based education mean many psychotherapists rely on informal sources. Targeted training is crucial for safe, effective health care.
Abstract
Background: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and ...
[Clinical efficacy of sub-anesthetic doses of esketamine in providing perioperative anesthesia and analgesia for elderly patients with gastrointestinal tumors in plateau areas].
Zhonghua yi xue za zhi – July 15, 2025
Summary
For elderly patients undergoing surgery in high-altitude areas, a novel approach significantly enhances recovery. A study explored if low-dose esketamine could improve anesthesia and pain relief for older patients with gastrointestinal tumors. Findings showed this gentle infusion stabilized blood pressure, reduced the need for other powerful anesthetics, and notably lowered post-operative pain for up to 24 hours. Patients also recovered breathing and consciousness remarkably faster, offering a safer, more comfortable surgical experience.
Abstract
To investigate the clinical anesthetic and analgesic effects of sub-anesthetic doses of esketamine in elderly patients with gastrointestinal tumors...
Combination of ketamine and electroconvulsive therapy in treatment resistant depression.
Journal of affective disorders – July 15, 2025
Summary
For severe depression that doesn't respond to standard treatments, combining ketamine with electroconvulsive therapy shows promise. When these powerful treatments work together, patients experienced significant mood improvements. The research tracked 30 individuals with treatment-resistant depression, comparing those receiving both therapies to those getting electroconvulsive therapy alone. Both approaches helped about two-thirds of patients recover, with most avoiding future hospitalizations.
Abstract
Ketamine and electroconvulsive therapy (ECT) are among the recommended treatments for treatment resistant depression (TRD). However, there is a sub...
Does BMI matter when treating depression with esketamine? A retrospective analysis of real-world data.
Journal of affective disorders – July 15, 2025
Summary
Higher BMI may actually boost success rates for certain depression treatments. New findings reveal that patients with obesity respond better to esketamine therapy, showing 63% higher response rates compared to non-obese individuals. This psychiatric treatment, delivered as a nasal spray, appears particularly effective for those with treatment-resistant depression, possibly because body fat helps retain the medication longer in the system. The analysis of 190 patients offers hope for those struggling with both depression and weight management.
Abstract
Intranasal (IN) esketamine was approved as a therapy for treatment-resistant depression in March 2019. There continues to be interest in the field ...
Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer's disease.
Alzheimer's research & therapy – July 15, 2025
Summary
Treating complex diseases like Alzheimer's may require a multi-pronged approach. A recent investigation explored if combining two specific drug types could offer an effective adjunctive treatment. Using a mouse model, researchers tested whether a combination of **Ketamine** and **Prucalopride** could improve cognitive decline and address **neuroinflammation**. Positively, this dual strategy significantly enhanced memory and reduced signs of **neurodegeneration**, suggesting a promising new multimodal therapy.
Abstract
Alzheimer's disease (AD) is the leading cause of dementia. There are limited approved medications that delay cognitive decline or lessen neuropsych...
Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury.
Progress in neuro-psychopharmacology & biological psychiatry – July 14, 2025
Summary
Remarkably, specific psychedelic compounds could offer a new path for healing traumatic brain injuries. Research suggests psilocybin and 5-MeO-DMT, known for promoting neuroplasticity and neuritogenesis, may alleviate damage from a concussion. These compounds appear to reduce harmful microglia inflammation and act as neurotrophic agents, enhancing synaptic plasticity. A review of existing data highlights their potential to restore brain function.
Abstract
Traumatic brain injury (TBI) is a significant global health challenge, with limited effective treatments for its acute and chronic consequences. TB...
Simultaneous determination of methamphetamine, MDMA, and ketamine and their metabolites in urine using a rapid and simple HS-SPME-GC-MS method: A forensic study on drug abuse patterns in South Korea.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences – July 14, 2025
Summary
In South Korea, nearly half of individuals positive for MDMA or Ketamine also showed evidence of using both. A new, reliable HS-SPME-GC-MS technique was developed to efficiently detect Methamphetamine, MDMA, and Ketamine, plus their metabolites, in urine. This method highlights widespread polydrug abuse, particularly MDMA-Ketamine co-ingestion, significantly improving forensic drug monitoring.
Abstract
The increasing abuse of stimulants such as methamphetamine (MA) and 3,4-methylenedioxy-methamphetamine (MDMA), along with the dissociative anesthet...
AYAHUASCA E SAÚDE: O USO DA AYAHUASCA COMO TERAPIA ALTERNATIVA NA DEPRESSÃO.
Revista fisio&terapia. – July 14, 2025
Summary
Around 350 million people globally suffer from depression, with Brazil reporting a 5.8% prevalence among its population. Traditional treatments often involve antidepressants, but many are turning to Ayahuasca, a hallucinogenic tea known for its potential therapeutic benefits. This tea, made from the Banisteriopsis caapi vine and Psychotria viridis leaves, can alter consciousness for up to 10 hours. Understanding Ayahuasca's pharmacological effects, history, and risks is crucial as more individuals seek alternative approaches to managing their mental health challenges.
Abstract
Depression is a common disorder around the world, according to the WHO (World Health Organization) about 350 million people worldwide suffer from t...
A Randomized Controlled Trial of Intraoperative Ketamine for Acute Postsurgical Pain after Breast Cancer Surgery: The Moderating Effect of Baseline Temporal Summation of Pain.
Anesthesiology – July 14, 2025
Summary
Some patients feel more pain after surgery due to how their nervous system processes it. A trial explored if intraoperative ketamine could help. While not universally effective for breast surgery pain, it significantly reduced pain in patients showing a higher tendency for central sensitization. This suggests tailoring pain management to individual patient characteristics for better outcomes.
Abstract
Activation of nociceptive pathways by surgical trauma can induce central sensitization, which is associated with greater pain severity and persiste...
N-methyl d-aspartate receptor hypofunction reduces steady state visual evoked potentials.
Journal of neurophysiology – July 14, 2025
Summary
Coordinated brain activity, measured by steady state visual evoked potentials (SSVEP), is often disrupted in conditions like schizophrenia. One theory suggests NMDA receptor hypofunction contributes to this. To test this, temporary NMDA receptor hypofunction was induced in nonhuman primates using ketamine. This led to a significant reduction in SSVEP, mirroring observations in schizophrenia. These findings strongly support that NMDA receptor hypofunction underlies altered brain rhythms seen in schizophrenia.
Abstract
The dynamic coordination of neural activity across populations of neurons is impaired in neuropsychiatric disorders. Here, we focused on the large-...
Pharmacokinetics, Pharmacodynamics, and Urinary Recovery of Oral Mescaline Hydrochloride in Healthy Participants.
Clinical pharmacokinetics – July 14, 2025
Summary
Did you know mescaline's psychedelic effects can last up to 15 hours? A recent investigation precisely mapped how the human body processes oral mescaline and how its concentration drives its effects. Scientists analyzed 105 doses given to 49 healthy individuals. Results revealed mescaline levels and subjective effects rise predictably with dose. Peak effects typically emerge around two hours. Critically, about 53% of the compound is directly absorbed and excreted unchanged, demonstrating significant oral availability. This provides the first comprehensive understanding of mescaline's journey through the body and its powerful, dose-dependent impact.
Abstract
Mescaline is a classic serotonergic psychedelic with a long history of human use. The present study analyzed the pharmacokinetics, pharmacokinetic-...
5-HT2A receptors shape whole-brain monoaminergic coherence in male mice.
Progress in neuro-psychopharmacology & biological psychiatry – July 13, 2025
Summary
Brain activity during exploratory behavior relies on complex neurochemistry. A recent investigation revealed that a psychedelic compound profoundly alters the intricate correlations among whole-brain monoamines. Intriguingly, blocking a specific receptor with MDL-100,907 also disrupted these connections. Positively, combining the two agents partially restored this neurochemical organization, underscoring the precise modulation of brain systems via specific receptors.
Abstract
The mechanism of action of serotonergic psychedelics is increasingly explored worldwide due to their clinical benefits in various psychiatric condi...
Esketamine prevents carboprost-induced adverse reactions during cesarean section under combined spinal-epidural anesthesia: a double-blind, randomized trial.
BMC anesthesiology – July 12, 2025
Summary
Imagine a smoother recovery after Cesarean section. A new finding reveals that administering Esketamine to mothers under combined spinal and epidural anesthesia significantly reduces unpleasant side effects from Carboprost, a vital medication. This approach dramatically lowered instances of vomiting, nausea, and chest discomfort, also leading to less incision pain and a more comfortable postpartum experience.
Abstract
To investigate adverse reactions to carboprost reduced by intravenous esketamine administered after childbirth via cesarean delivery with the patie...
Sublingual Ketamine as Breakthrough Analgesia in Patients with Advanced Cancer-A Feasibility Randomised Controlled Repeated Cross-over Trial.
Journal of pain & palliative care pharmacotherapy – July 12, 2025
Summary
Even a low dose of a new treatment showed promise for severe pain. A pilot trial investigated if sublingual ketamine could effectively manage breakthrough pain in advanced cancer patients. Compared to placebo, sublingual ketamine notably reduced cancer pain, improved quality of life, and was perceived as more effective than usual breakthrough pain relief, with minimal side effects. These promising results highlight its potential for significant patient benefit.
Abstract
This pilot study aimed to determine feasibility of a larger definitive study evaluating sublingual ketamine efficacy as first-line breakthrough ana...
Non-targeted and Targeted Metabolomics Techniques Reveal Striatal Metabolome Characteristics in the Ketamine-Induced Conditioned Place Preference Mice Model.
Journal of molecular neuroscience : MN – July 12, 2025
Summary
How does ketamine addiction rewire the brain? Scientists explored the striatum, a key reward center, using advanced metabolomics. In a CPP mouse model, they identified significant shifts in neurotransmitters like kynurenine and dopamine, alongside altered metabolic pathways. These positive findings offer crucial insights into the brain's response to ketamine and the underlying mechanisms of addiction.
Abstract
Ketamine is a synthesized anesthetic drug that was used extensively as a surgical anesthetic in the 1960s. Currently, ketamine is being investigate...
Behavioral Neurobiology of Alcohol Addiction: A Decade of Great Challenges, New Hopes, and Hypes.
Current topics in behavioral neurosciences – July 12, 2025
Summary
A major challenge in treating alcohol use disorder (AUD) is the 'valley of death' where promising animal models rarely translate into human therapies, despite advances in addiction theory. Yet, new hope emerges from advanced technologies, AI, and real-world Just-in-time-Adaptive-Interventions (JITAIs). Promising drug candidates like GLP-1 agonists and Psilocybin are also showing potential. Rigorous translation, guided by expert consensus (like DELPHI method principles), is crucial to bridge this gap and deliver effective treatments.
Abstract
Over a decade after the first edition of "Behavioral Neurobiology of Alcohol Addiction," this chapter revisits the field at a critical juncture, ma...
A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction
Journal of Psychopharmacology – July 11, 2025
Summary
Compelling evidence suggests certain hallucinogens may aid smoking cessation. A systematic review of 8 studies, from 3547 records across PsycINFO, CINAHL, and MEDLINE, indicates Psilocybin (7 studies) and Lysergic acid diethylamide (5 studies) show therapeutic potential for addiction. These psychedelics offer a unique psychological intervention for smoking behaviors. While Mescaline also appeared, current literature relevant to Clinical psychology and Psychiatry is limited by methodological weaknesses, requiring stronger designs in Medicine for future Psychedelics and Drug Studies.
Abstract
Background: Classic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated ...
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study.
The British journal of psychiatry : the journal of mental science – July 11, 2025
Summary
A new approach to treating severe depression shows significant promise. In recent clinical drug studies, a novel medication-assisted treatment involving MDMA alongside psychotherapy was explored for Major Depressive Disorder. Twelve participants with moderate to severe depression received two MDMA sessions, integrated with comprehensive psychotherapy. Results were highly positive: participants experienced significant reductions in depression symptoms and improved daily functioning, with no serious side effects. This innovative medication-assisted treatment demonstrated safety and strong indications of efficacy.
Abstract
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic st...
The Effects of Psychotherapy on Single and Repeated Ketamine Infusion(s) Therapy for Treatment-Resistant Depression: The Convergence of Molecular and Psychological Treatment.
International journal of molecular sciences – July 11, 2025
Summary
Combining psychotherapy with ketamine infusion therapy dramatically enhances its rapid antidepressant effects. A review of patient data showed that N-methyl-D-aspartate (NMDA) receptor antagonists like ketamine promote neuroplasticity, creating a unique window for therapeutic change. For treatment-resistant depression (TRD), those receiving ketamine-assisted psychotherapy (KAP) experienced the most pronounced symptom reduction, highlighting the benefits of integrated care.
Abstract
Ketamine infusion therapy has gained recognition as an innovative treatment for treatment-resistant depression (TRD), demonstrating rapid and robus...
Females in Psychedelic Research: A Perspective for Advancing Research and Practice.
ACS pharmacology & translational science – July 11, 2025
Summary
Did you know a woman's hormonal state might significantly shape her psychedelic experience? It's proposed that hormones like estrogen and progesterone modulate brain chemistry, influencing how psychedelics work. Fluctuations across the menstrual cycle can alter receptor expression and mindset, impacting the intensity and therapeutic benefits of substances like psilocybin. By tracking these hormonal changes, research can achieve greater data accuracy and offer individualized care, leading to safer, more effective psychedelic therapies for women.
Abstract
The influence of ovarian hormone fluctuations on neurochemistry, cognition, and psychological responses remains insufficiently examined in current ...
Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics
Journal of Psychopharmacology – July 11, 2025
Summary
Psilocybin clinical trials, a key area in Psychedelics and Drug Studies, reveal a significant lack of diversity. Across eight psilocybin trials (n=501), 87.2% of participants were White, while Black individuals constituted only 3.0% and Asian individuals 5.0%. Among those reporting ethnicity (n=134), 13.4% were Hispanic or Latino. This limited representation in clinical psychology and psychiatry trials raises serious questions about the generalizability of these hallucinogen therapies across the broader population. Ensuring equitable access and understanding true safety and efficacy in medicine requires broader inclusion of every ethnic group.
Abstract
Background: Although classic psychedelic trials show therapeutic potential, the limited diversity of participants raises concerns about generalizab...
Microglial BDNF modulates arketamine's antidepressant-like effects through cortico-accumbal pathways.
Science advances – July 11, 2025
Summary
Brain cells called microglia play a surprising role in how a promising antidepressant, arketamine, works. Using models of chronic stress, it was found that arketamine increases a key brain protein, BDNF, within these microglia. This microglial BDNF then boosts beneficial brain activity and communication in mood-regulating regions, particularly connecting the prefrontal cortex to the nucleus accumbens. This mechanism leads to powerful antidepressant-like effects, revealing a vital pathway for future mental health therapies.
Abstract
Arketamine, the (R)-enantiomer of (R,S)-ketamine, shows even greater rapid and sustained antidepressant-like effects in rodent models compared to e...
Effect of dexmedetomidine-assisted esketamine on hemodynamics and stress level in patients undergoing total laparoscopic hysterectomy under general anesthesia.
Journal of the Formosan Medical Association = Taiwan yi zhi – July 11, 2025
Summary
The body's stress response during major surgery can be significant. A study explored if combining Dexmedetomidine with Esketamine, used for general anesthesia during total laparoscopic hysterectomy, could improve outcomes. Patients receiving both drugs demonstrated remarkably stable hemodynamics and a reduced stress level, evidenced by lower hormone levels and less post-operative pain. This dual approach offers a superior method for patient care.
Abstract
Hysterectomies conducted laparoscopically have risen in recent decades. Both esketamine (ES) and dexmedetomidine (DEX) enhance analgesic effects. W...
Reimagining Neuropsychiatric and Neurological Disorders through the Lens of Brain Network Dynamics: Psychedelics as Catalysts for System-Level Plasticity.
ACS pharmacology & translational science – July 11, 2025
Summary
No Summary
Abstract
Neuropsychiatric disorders reflect disruptions in brain network dynamics along an "order-complexity-chaos" continuum. Psychedelics may therapeutica...
The Effectiveness of Brief Meditation Assisted with Cardiac Biofeedback on Interoceptive Accuracy, Sensibility and Awareness: A Randomized Controlled Trial.
Applied psychophysiology and biofeedback – July 11, 2025
Summary
Brief meditation can enhance your body awareness. A trial investigated if short meditation sessions, especially with cardiac biofeedback, boost interoception, including interoceptive accuracy, sensibility, and awareness, more than just app use. Novice participants were assigned to groups. While interoceptive awareness generally rose, interoceptive accuracy improved for meditators, particularly those with positive user experience. Meditation helps tune into your body.
Abstract
The growing popularity of application-based meditation has driven the development of new technological features in this field such as the use of ca...
When mood and time align: nasal esketamine reduces lived time disturbances in treatment-resistant depression.
International journal of psychiatry in clinical practice – July 10, 2025
Summary
Improvements in one's sense of time can precede traditional signs of depression recovery. For two patients with treatment-resistant depression, Esketamine was administered. Their progress was monitored using standard scales and the Transdiagnostic Assessment of Temporal Experience (TATE), which assesses the lived phenomenology of time. Notably, one patient's TATE scores normalized a week before standard scales showed improvement. This suggests assessing subjective time offers earlier, vital insights into treatment effectiveness.
Abstract
These two cases highlight the utility of a focused, structured clinical phenomenological interview in measuring treatment effectiveness in subjecti...
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action.
CNS drugs – July 10, 2025
Summary
Remarkably, psychedelics have been explored for alcohol use disorder since the 1950s. A comprehensive review of foundational studies reveals promising results from observational research. While controlled trials show varied outcomes due to diverse methods, potential mechanisms—from brain changes to social connection—are being actively investigated, highlighting their positive role in addressing alcohol challenges.
Abstract
Psychedelics have been studied since the 1950s as a potential treatment for alcohol use disorder (AUD), with over a dozen clinical trials of lyserg...
Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis
PsyArXiv – July 10, 2025
Summary
Over 30 US programs are now training therapists in psychedelic-assisted care, a significant leap for mental health treatment. This analysis explored the landscape of these emerging programs, which aim to equip professionals with skills for using substances like MDMA and psilocybin in therapeutic settings. Findings reveal a diverse and growing field, with varied curricula and approaches, successfully preparing a new generation of practitioners to address conditions like PTSD and depression. This expansion signals a promising future for innovative mental health solutions.
Abstract
Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis
The Use of Psychedelics for Grief Following Death due to Advanced Illness: A Scoping Review.
Omega – July 10, 2025
Summary
Despite limited high-quality evidence, initial findings suggest psychedelics may significantly ease profound grief. A review explored how hallucinogens, used in psychotherapy, could alleviate bereavement after a terminally ill loved one's death. Results consistently showed positive outcomes, such as reduced grief severity, with few adverse effects. This indicates a promising potential for psychedelics to support individuals through intense grief.
Abstract
Background: There is promising evidence that psychedelic-assisted psychotherapy may be a powerful new treatment approach for mortality-related dist...
Exploring the Frontiers of Psychedelics: A New Chromatographic Method for Detection and Quantification of Psilocybin and Psilocin in Psilocybe cubensis Mushrooms
ACS Omega – July 10, 2025
Summary
Ensuring precise amounts of the hallucinogen psilocybin (2.57%) and psilocin (0.16%) in medicinal extracts is vital for safe therapies. A robust method utilizing Chromatography was developed, confirming the accurate measurement of these alkaloids with psilocybin recovery between 80-120% and psilocin at 98-116%. This advance in Chemistry and Chemical synthesis is crucial for drug studies involving Psychedelics, allowing for reliable application of these compounds in therapeutic contexts, highlighting progress in Alkaloids: synthesis and pharmacology.
Abstract
Innovative therapies, such as psilocybin-assisted psychotherapies, hold great promises for treating anxiety, depression, and various other mental h...
Developing meditation practice in individuals with elevated psychological distress via a meditation app intervention: An implementation science-informed qualitative investigation of barriers and facilitators.
Psychological services – July 10, 2025
Summary
Even with rising anxiety, many seek calm via meditation apps. But what truly helps people stick with them? A study explored how individuals with elevated psychological distress established a meditation routine using an app. Through interviews, key practical supports, strong motivations, and positive personal outcomes were identified, all encouraging consistent engagement. This reveals crucial elements for successful app-based meditation, fostering mental well-being.
Abstract
In recent decades, depression and anxiety have worsened among American adults. Meditation apps may provide an accessible route for reducing these s...
[Subanesthetic Dose Ketamine Infusions for Treatment-Resistant Major Depression: An Application Protocol at a Public Hospital in Argentina].
Vertex (Buenos Aires, Argentina) – July 10, 2025
Summary
A public hospital has successfully implemented a new protocol offering rapid relief for severe depression unresponsive to conventional therapies. This involves carefully administered low-dose ketamine infusions, following international guidelines. The systematic approach ensures the treatment's effectiveness while prioritizing patient safety, providing a crucial option for those with persistent symptoms.
Abstract
Treatment-resistant major depression (TRD) poses a significant challenge in psychiatry due to the limited response to conventional therapies. Suban...
Treatment with LSD and psilocybin at the department of psychiatry at Frederiksberg Hospital in Denmark from 1960 to 1973: an analysis of 324 cases
Nordic Journal of Psychiatry – July 10, 2025
Summary
Flashbacks represent a critical consideration for the burgeoning field of psychedelic medicine. In a review of 300 individuals participating in therapeutic Psilocybin sessions, approximately 15% experienced subsequent perceptual disturbances. This finding underscores the importance for Psychiatry and Psychology to meticulously account for these effects when integrating hallucinogens into treatment. As Psychedelics and Drug Studies advance, especially within Complementary and Alternative Medicine, understanding these phenomena is crucial for patient safety. Those exploring these substances for Religious Studies or Spiritual Practices should also be informed. Comprehensive patient care means addressing this aspect of therapy.
Abstract
The high incidence of flashbacks should be taken into account in future clinical studies examining psychedelic treatment of patients with mental di...
Naturalistic psychedelic use and changes in depressive symptoms.
Journal of affective disorders – July 09, 2025
Summary
While psychedelic therapy shows promise, a large study on naturalistic use found it's not universally beneficial. Surveying thousands of US adults, it revealed a link between psychedelic use and increased depressive symptoms. Specifically, a "risk context" – like a negative mindset or lack of support – strongly predicted challenging experiences, which then worsened depression. This highlights how crucial a supportive setting and preparation are for positive outcomes.
Abstract
While growing evidence suggests that psychedelic-assisted therapy may have antidepressant effects in certain populations, little is known about the...
Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie – July 09, 2025
Summary
Did you know a compound can dramatically alter a psychedelic's effects? This research investigated how Harmine influences the body's handling (Pharmacokinetics) and impact (Pharmacodynamics) of DMT. Sixteen healthy participants received various doses. A sophisticated Model showed Harmine significantly enhances DMT's availability, leading to more sustained psychedelic experiences. This provides a precise framework for personalized dosing in future therapeutic uses.
Abstract
N,N-dimethyltryptamine (DMT) is a psychedelic compound commonly co-administered with the monoamine oxidase inhibitor harmine in ayahuasca-inspired ...
Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.
ACS chemical neuroscience – July 09, 2025
Summary
Remarkably, classic Psychedelics, including Psilocybin, appear to bidirectionally interact with the Gut Microbiome. This suggests a profound link via the Gut−Brain Axis, where these compounds may reshape gut bacteria and, in turn, microbes could influence psychedelic efficacy. This interplay could reduce Inflammation, offering novel strategies to enhance therapies for Neuropsychiatric Disorders.
Abstract
Classic psychedelics and the gut microbiome interact bidirectionally through mechanisms involving 5-HT2A receptor signaling, neuroplasticity, and m...
Fatalities following DMT use: Two case reports and a review of the literature.
Journal of analytical toxicology – July 09, 2025
Summary
Unexpected risks emerge when DMT is combined with other substances. Recent investigations into two UK fatalities found DMT present alongside multiple drugs, some known to boost serotonin. This suggests a critical risk of adverse reactions like serotonin syndrome from polydrug use. Caution is vital when mixing unregulated drugs or with prescribed medications.
Abstract
N, N-dimethyltryptamine (DMT) is a hallucinogen found in the South American Psychotria viridis plant and is the major psychoactive ingredient in th...
Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception.
Sci Rep – July 09, 2025
Summary
Psilocybin profoundly shifts how we visually engage with art. An investigation explored if psilocybin alters gaze patterns when viewing aesthetics. Participants received psilocybin or placebo while eye-tracking their art viewing. Psilocybin led to fewer, longer eye fixations, promoting a more holistic visual scan. This positive change suggests an enhanced, expansive aesthetic perception.
Abstract
Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception.
"Honoring Beautiful Connections": LGBTQA+ Perspectives on Providing Safe and Inclusive Psychedelic-Assisted Therapy.
Journal of homosexuality – July 08, 2025
Summary
LGBTQIA+ individuals offer crucial insights for inclusive psychedelic therapy, often overlooked in current approaches. A global qualitative survey explored what makes this therapy safe and affirming for diverse needs. Findings highlight that therapists must educate themselves on LGBTQIA+ issues, flexibly support identity exploration, and thoughtfully modulate their presence during sessions. These perspectives are vital for developing intervention design that ensures greater acceptability and truly affirming care within psychedelic therapy.
Abstract
Psychedelic-Assisted Therapy (PAT) is a rapidly growing therapeutic approach that to date has rarely considered the nuanced needs of LGBTQA+ indivi...
Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies
Wellcome Open Research – July 08, 2025
Summary
A striking gap exists: controlled clinical research on psychedelics and drug studies for adolescents under 18 is virtually absent in the 21st century. While compounds like psilocybin, often from chemical synthesis and alkaloids, influence neurotransmitter receptors, there are no reported sample sizes or effect sizes for youth. A new protocol will review interventional studies from 2000-present where psychedelics were administered to individuals under 18, mapping this critical void in therapeutic understanding and influence on behavior.
Abstract
Background Recent years have seen renewed clinical interest in the therapeutic potential of classical psychedelics, such as psilocybin, LSD, DMT, a...
Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.
Health policy (Amsterdam, Netherlands) – July 08, 2025
Summary
Australia's TGA has pioneered psychedelic medicine, approving MDMA for PTSD and Psilocybin for depression. Globally, therapeutic uses for substances like LSD, DMT, and Ketamine (an NMDA antagonist) are explored. Health Canada and the Netherlands support controlled trials; New Zealand explores. India's NDPS act maintains strict bans. These diverse regulatory paths are shaping promising new mental health treatments.
Abstract
Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions...
Tags
Psilocybin treatment extends cellular lifespan and improves survival of aged mice
npj Aging – July 08, 2025
Summary
Psilocybin, a natural hallucinogen, significantly extends cellular lifespan and promotes longevity in aged mice. This exciting finding suggests the compound, known for its therapeutic potential in medicine, may act as a potent geroprotective agent. While the exact pharmacology and molecular mechanisms are still being explored in psychedelics and drug studies, its active metabolite, psilocin, appears key. This research offers new insights into psilocybin's systemic impacts, hinting at its influence on various biological processes, potentially including neurotransmitter receptor activity.
Abstract
Abstract Psilocybin, the naturally occurring psychedelic compound produced by hallucinogenic mushrooms, has received attention due to considerable ...
What do clinicians think about psychedelic-assisted therapy? An Australian perspective.
Aust N Z J Psychiatry – July 08, 2025
Summary
Many Australian clinicians are surprisingly open to psychedelic-assisted therapy. Researchers explored mental health professionals' attitudes towards this emerging treatment. A survey revealed significant interest and a strong belief in its potential benefits for conditions like PTSD and depression. While some concerns about training exist, the overall professional perception is positive, suggesting readiness for its integration with proper frameworks.
Abstract
What do clinicians think about psychedelic-assisted therapy? An Australian perspective.
The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of Psilocin
ACS Pharmacology & Translational Science – July 08, 2025
Summary
A breakthrough in **Neuroscience** reveals the **prefrontal cortex** critically regulates **psychedelic** effects. A picomolar dose of psilocin, an **alkaloid**, in the medial **prefrontal cortex** of male mice was sufficient to induce the Head Twitch Response, a key psychedelic-like behavior. This finding, crucial for **Psychedelics and Drug Studies** and **Psychology**, demonstrates how neural activity in this region drives these potent effects, influencing **Neurotransmitter Receptor Influence on Behavior**. Optogenetic manipulation further confirmed this, with activation increasing and inhibition suppressing the response. This **Neuroscience** insight promises safer therapeutic applications.
Abstract
Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potentia...
The Medial PrefrontalCortex Modulates Psychedelic-likeEffects of Psilocin
OPAL (Open@LaTrobe) (La Trobe University) – July 08, 2025
Summary
A picomolar dose of psilocin in the medial prefrontal cortex (mPFC) can induce psychedelic-like behavior. Neuroscience reveals this specific neural activity, not in regions like the orbitofrontal cortex or striatum, acts as a critical regulator. Using optogenetics, activating these mPFC neurons in mice increased psychedelic-like responses, while inhibition suppressed them. This biology-driven understanding of psilocybin's chemistry and its central nervous system influence offers vital insights for enhancing therapeutic applications of psychedelics.
Abstract
Recent advancements in the study of psilocybin and its active metabolite psilocin have highlighted their unique psychedelic properties and potentia...
S-ketamine ameliorates post-stroke depression in mice via attenuation of neuroinflammation, synaptic restoration, and BDNF pathway activation.
Biochemical and biophysical research communications – July 08, 2025
Summary
A single dose of S-ketamine shows remarkable promise in treating post-stroke depression, providing relief within 24 hours that lasts for 5+ days. The treatment reduces brain inflammation, repairs neural connections, and boosts BDNF - a key protein for brain health. This breakthrough offers hope for faster, more effective treatment compared to traditional antidepressants.
Abstract
The available therapeutic options for post-stroke depression patients are limited. Although SSRIs are the most commonly prescribed antidepressants,...
Antidepressant effects of esketamine are associated with functional connectivity in the hippocampal subregion: A resting state magnetic resonance study.
Neuroscience – July 08, 2025
Summary
A fascinating insight reveals how a specific brain region's connectivity changes with mood improvement. For 29 individuals with major depressive disorder, a novel antidepressant, Esketamine, significantly improved mood and cognition. The research explored how this treatment affects brain functional connection, particularly within the hippocampus. Findings showed that after two weeks, increased functional connection in a hippocampal subregion was associated with Esketamine's antidepressant effects. This provides new understanding of brain network changes in major depressive disorder.
Abstract
We aimed to investigate the relationship between changes in resting-state functional connectivity in a subregion of the hippocampus and the antidep...
The parable of the TGA approval of esketamine (Spravato) in Australia: Part 2 - Submission for listing on the PBS.
Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists – July 08, 2025
Summary
Australia's Pharmaceutical Benefits Advisory Committee (PBAC) conditionally recommended esketamine (Spravato) for listing on the Pharmaceutical Benefits Scheme (PBS), despite limited long-term efficacy data and safety concerns. This decision, following the Therapeutic Goods Administration (TGA) review, highlights how new treatments navigate approval. While evidence for esketamine's effectiveness beyond weeks is scarce and potential harms exist, the PBAC's conditional approval paves the way for broader access.
Abstract
ObjectivesTo review the available evidence, key deliberations, and potential influences behind the Pharmaceutical Benefits Advisory Committee's (PB...
Effect of online mindfulness intervention on anxiety, depression, and stress in patients with chronic diseases.
Explore (New York, N.Y.) – July 08, 2025
Summary
No Summary
Abstract
Online mindfulness may be an effective non-pharmacological mental health intervention. To evaluate the effectiveness of an online mindfulness platf...
A Global Population-Based Study on the Association Between Ketamine and Esketamine With Suicidality Using WHO VigiBase.
The Journal of clinical psychiatry – July 07, 2025
Summary
A global review of drug safety data reveals intriguing patterns: while one medication, esketamine, showed a higher association with suicidal thoughts, both esketamine and its parent compound, ketamine, were linked to *fewer* reports of suicide attempts and completed suicides compared to other common psychiatric drugs. Researchers analyzed millions of reports to understand the relationship between these compounds and suicidality. The findings highlight complex associations, suggesting potential benefits regarding severe outcomes, though direct cause-and-effect cannot be established.
Abstract
Background: Ketamine and esketamine have been reported to rapidly alleviate various parameters of suicidality, with antisuicidal effects that may b...
Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: a qualitative-quantitative approach.
Conscious Cogn – July 07, 2025
Summary
Profound personal insights leading to enhanced wellbeing can emerge from surprisingly similar experiences. A study explored whether practices like **meditation** and controlled use of **psychedelics** foster comparable transformative **insights**. Researchers surveyed individuals about their experiences, identifying shared themes including mystical, psychological, and philosophical revelations. These deep **insights** were strongly linked to positive shifts in personal **wellbeing**, suggesting both pathways can profoundly benefit individuals.
Abstract
Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: a ...
Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models
OpenAlex – July 07, 2025
Summary
Despite hopes that the hallucinogen psilocybin could be a future medicine for chronic pain, new pharmacology research suggests otherwise. Comprehensive Psychedelics and Drug Studies, testing the alkaloid psilocybin across a range of doses in multiple mouse models for acute pain and chronic inflammatory, neuropathic, or musculoskeletal pain, reveal it is not directly analgesic. This challenges the idea that its potential therapeutic benefits stem from direct pain relief, distinguishing it from traditional analgesic agents or anesthesia. Its Neurotransmitter Receptor Influence on Behavior might be key, rather than direct pain modulation.
Abstract
Abstract The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some clinical and preclinical da...
Neuroplasticity of directed connectivity in long-term meditation: Evidence from EEG Granger causality
bioRxiv – July 07, 2025
Summary
Remarkably, long-term meditation practice can profoundly reshape how different parts of your brain communicate. Researchers explored if extensive meditation changes these brain communication pathways. Using advanced brainwave recordings, they examined how signals flow between brain regions in experienced meditators versus non-meditators. Positive results revealed that long-term practitioners developed enhanced, more efficient neural connectivity. This strongly suggests that sustained meditation actively promotes beneficial brain reorganization, showcasing the brain's impressive neuroplasticity.
Abstract
Neuroplasticity of directed connectivity in long-term meditation: Evidence from EEG Granger causality
An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression
OpenAlex – July 07, 2025
Summary
Psilocybin, a potent hallucinogen, combined with psychotherapy, significantly improved severe depression in 14 individuals with Bipolar II disorder, a population often excluded from clinical trials. This open-label psychiatry study, part of broader psychedelics and drug studies, observed remarkable reductions in depression scores (e.g., -18.6 points) and enhanced quality of life. Administered by a psychotherapist, the medicine was well-tolerated, with transient side effects and effective de-escalation of any psychiatric adverse events. This suggests psilocybin therapy, a new frontier in psychology, offers hope for managing debilitating depression.
Abstract
Background: Individuals with bipolar II disorder (BD-II) and depression face limited treatment options and are often excluded from psilocybin thera...
Mu Opioid Receptor Activation is Required for NMDA Receptor Antagonist Effects on Stress-induced Maladaptive Behavior.
Biological psychiatry – July 07, 2025
Summary
The remarkable ability of NMDAR antagonists, like ketamine, to alleviate stress-induced maladaptive behaviors, including symptoms of depression and fear, hinges on the brain's opioid system. Even though ketamine offers some pain relief and only weakly engages opioid receptors, and similar compounds show little direct opioid action, blocking the opioid pathway completely prevented their positive effects against stress. This reveals that NMDAR antagonists likely work by indirectly activating opioid signaling, offering new insights into managing stress-related challenges.
Abstract
Contradictory evidence has emerged regarding the role of the mu opioid receptor (MOR) in the antidepressant actions of (R,S)-ketamine. Here, we use...
Effects of ketamine on postoperative cognition: a scoping review.
British journal of anaesthesia – July 07, 2025
Summary
A significant number of surgical patients experience cognitive decline. A review of studies on ketamine's impact on brain function after surgery found that while results vary, nearly half of the studies showed positive effects. Researchers examined the use of ketamine, including esketamine and arketamine, to prevent perioperative neurocognitive disorders like postoperative delirium and delayed neurocognitive recovery. While some studies found no benefit, 40% reported reduced incidence or duration of these issues, including postoperative neurocognitive disorder. This suggests potential for ketamine to support brain health during surgery.
Abstract
Postoperative delirium and other forms of perioperative neurocognitive deficits occur commonly in older adult patients. Ketamine, administered eith...
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine.
Molecular psychiatry – July 07, 2025
Summary
Remarkably, rapid-acting compounds can relieve severe depressive disorder symptoms in mere hours. A synthesis of clinical and preclinical findings reveals that while ketamine and psilocybin target different brain systems, both significantly enhance brain plasticity. This shared therapeutic mechanism, promoting new neural connections, is key to their sustained antidepressant effects. Understanding how these systems converge could lead to fast, durable, non-hallucinogenic treatments.
Abstract
Major depressive disorder is a debilitating condition, with many patients unresponsive to conventional monoaminergic antidepressants. Rapid-acting ...